{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:11:37Z","timestamp":1769839897912,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2016.25","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T14:29:01Z","timestamp":1463149741000},"page":"e420-e420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical response to everolimus in a patient with Hodgkin\u2019s lymphoma harboring a TSC2 mutation"],"prefix":"10.1038","volume":"6","author":[{"given":"G F","family":"Perini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P V","family":"Campregher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F P S","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"issue":"Suppl 1","key":"BFbcj201625_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/hon.2210","volume":"33","author":"JM Connors","year":"2015","unstructured":"Connors JM . I. Hodgkin lymphoma: special challenges and solutions. Hematol Oncol 2015; 33 (Suppl 1): 21\u201324.","journal-title":"Hematol Oncol"},{"key":"BFbcj201625_CR2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","volume":"96","author":"A Josting","year":"2000","unstructured":"Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A . Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280\u20131286.","journal-title":"Blood"},{"key":"BFbcj201625_CR3","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812\u20131821.","journal-title":"N Engl J Med"},{"key":"BFbcj201625_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311\u2013319.","journal-title":"N Engl J Med"},{"key":"BFbcj201625_CR5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320\u2013324.","journal-title":"Am J Hematol"},{"key":"BFbcj201625_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis C","year":"1993","unstructured":"European Chromosome 16 Tuberous Sclerosis C. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305\u20131315.","journal-title":"Cell"},{"key":"BFbcj201625_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/520389a","volume":"520","author":"V Marx","year":"2015","unstructured":"Marx V . Cancer: a most exceptional response. Nature 2015; 520: 389\u2013393.","journal-title":"Nature"},{"key":"BFbcj201625_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-11-0028","volume":"1","author":"S Durinck","year":"2011","unstructured":"Durinck S, Ho C, Wang NJ, Liao W, Jakkula LR, Collisson EA et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 2011; 1: 137\u2013143.","journal-title":"Cancer Discov"},{"key":"BFbcj201625_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K","volume":"14","author":"Y Niida","year":"1999","unstructured":"Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J, Beauchamp RL et al. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat 1999; 14: 412\u2013422.","journal-title":"Hum Mutat"},{"key":"BFbcj201625_CR10","doi-asserted-by":"publisher","first-page":"13571","DOI":"10.1073\/pnas.202476899","volume":"99","author":"AR Tee","year":"2002","unstructured":"Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J . Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA. 2002; 99: 13571\u201313576.","journal-title":"Proc Natl Acad Sci USA."},{"key":"BFbcj201625_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J . Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13: 1259\u20131268.","journal-title":"Curr Biol"},{"key":"BFbcj201625_CR12","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1101\/gad.1110003","volume":"17","author":"K Inoki","year":"2003","unstructured":"Inoki K, Li Y, Xu T, Guan KL . Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17: 1829\u20131834.","journal-title":"Genes Dev"},{"key":"BFbcj201625_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1126\/science.1226344","volume":"338","author":"G Iyer","year":"2012","unstructured":"Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.","journal-title":"Science"},{"key":"BFbcj201625_CR14","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","volume":"371","author":"N Wagle","year":"2014","unstructured":"Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371: 1426\u20131433.","journal-title":"N Engl J Med"},{"key":"BFbcj201625_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1471-2407-13-250","volume":"13","author":"A Mark","year":"2013","unstructured":"Mark A, Hajdu M, Varadi Z, Sticz TB, Nagy N, Csomor J et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease\u2014a combined tissue microarray, in vitro and in vivo study. BMC Cancer 2013; 13: 250.","journal-title":"BMC Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201625","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T10:47:34Z","timestamp":1718534854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"alternative-id":["BFbcj201625"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.25","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]},"assertion":[{"value":"13 May 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PVC, SA and JSR are employees of Foundation Medicine Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}